Liquidia Cites UTC’s Failed Appeal in Push for Yutrepia Approval

Liquidia Corp.'s legal battle to launch a treatment for a rare lung disease that would rival United Therapeutics Corp.'s blockbuster Tyvaso inched ahead in a Delaware district court, where Liquidia is touting a favorable Federal Circuit ruling as clearance to move ahead.

Liquidia urged Judge Richard G. Andrews to remove part of his 2022 judgment blocking approval of its drug, Yutrepia. The company cited the US Court of Appeals for the Federal Circuit’s Tuesday decision rejecting UTC’s bid to revive voided US Patent No. 10,716,793. The patent covers UTC’s Tyvaso, which had US sales of $1.21 billion in 2023. ...